TheJakartaPost

Please Update your browser

Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.

Jakarta Post

Indonesia puts convalescent plasma on pedestal. But how effective is it?

The government recently kicked off a national campaign to encourage COVID-19 survivors to donate their convalescent plasma for patients, despite other countries having halted the treatment following undesired results.

Ardila Syakriah (The Jakarta Post)
Premium
Jakarta
Tue, January 26, 2021

Share This Article

Change Size

Indonesia puts convalescent plasma on pedestal. But how effective is it? A nurse treats a COVID-19 patient at Bogor General Hospital in Bogor, West Java, on Sept. 3, 2020. (AFP/Adek Berry)

T

he government recently kicked off a national campaign to encourage COVID-19 survivors to donate their convalescent plasma for patients, as clinical trials are ongoing in Indonesia, despite other countries having halted their trials following undesired results.

Coordinating Human Development and Culture Minister Muhadjir Effendy cited a preliminary study by Saiful Anwar Regional General Hospital (RSUD) in Malang, East Java, which found patients with severe cases who received the experimental treatment had a 100 percent rate of recovery and critical patients had an 85 percent rate of recovery.

Without disclosing further details on the study, Muhadjir said "the preliminary study can be used to predict the use of convalescent plasma for COVID-19 recovery as very meaningful".

But clinical trials abroad, as well as experts at home -- both involved and not involved in local trials -- have rather doubted the therapy's effectiveness in critical cases.

Convalescent plasma therapy uses blood from COVID-19 survivors that is expected to contain enough antibodies to help fight off the virus. The blood goes through certain processes, leaving behind a yellow-colored liquid that is given to patients.

The therapy, which appears to have gained traction in Indonesia and even outside trial settings, might depend on whether the donors had enough specific neutralizing antibodies -- not just any other antibodies. Neutralizing antibodies are those capable of binding the virus, preventing it from entering the hosts' cells. The higher the antibody levels and the more severe the illness suffered by these survivors, the better their blood is likely to be for treating others.

Read also: Indonesia begins large-scale trials of COVID-19 blood plasma therapy

to Read Full Story

  • Unlimited access to our web and app content
  • e-Post daily digital newspaper
  • No advertisements, no interruptions
  • Privileged access to our events and programs
  • Subscription to our newsletters
or

Purchase access to this article for

We accept

TJP - Visa
TJP - Mastercard
TJP - GoPay

Redirecting you to payment page

Pay per article

Indonesia puts convalescent plasma on pedestal. But how effective is it?

Rp 29,000 / article

1
Create your free account
By proceeding, you consent to the revised Terms of Use, and Privacy Policy.
Already have an account?

2
  • Palmerat Barat No. 142-143
  • Central Jakarta
  • DKI Jakarta
  • Indonesia
  • 10270
  • +6283816779933
2
Total Rp 29,000
{

Your Opinion Matters

Share your experiences, suggestions, and any issues you've encountered on The Jakarta Post. We're here to listen.

Enter at least 30 characters
0 / 30

Thank You

Thank you for sharing your thoughts. We appreciate your feedback.